ABSTRACT The goals of the Biomedical Engineering (BME) Core within the Kansas Institute of Precision Medicine COBRE is two-fold: (1) Provide pioneering tools for the isolation of Liquid Biopsy Markers (LBMs) and small molecules of biological or clinical importance (Liquid Biopsy Unit); and (2) generate innovative microfluidic and nanofluidic devices in plastics for translational research (Plastics Engineering Unit). Outputs from both units has generated microfluidic tools to allow for the efficient isolation of disease biomarkers with the ability to process blood, plasma, saliva, and urine samples. The unique infrastructure of the BME Core and its outputs assist the KIPM COBRE members, including Research Project Leaders (RPLs) and Pilot Project Leaders (PPLs) as well as researchers outside of the KIPM to advance their science and effectively competing for federally funded research projects. Under the auspices of the BME Core, we have developed state-of-the-art assays and the associated microfluidic tools to support discovery and translational work. Some of our microfluidic tools are used for the efficient isolation of liquid biopsy markers, including extracellular vesicles (EVs), cell free molecules, and rare biological cells. EVs are an evolving liquid biopsy marker – related markers include lipid nanoparticles, and polymer nanoparticles – due to the high abundance found in biological fluids and the molecular cargo they carry in spite of their small size (<200 nm). Accurate characterization (i.e., size, concentration, presence of specific surface proteins) of these particles remains elusive requiring an array of optical instrumentation and highly trained personnel to infer vague conclusions from indirect measurements and assumptions to deduce their properties. Peer review data suggest that Spectradyne’s ARC™ particle analyzer delivers direct, accurate, and fast measurements that will help users of our BME Core for securing tangible results and enabling new discoveries. The Spectradyne’s technology allows for unique analyses of EVs and other nanoparticles such as polymer nanoparticles, liposomes, viruses, bacteria etc. that can play a central role in the field of precision medicine, the central theme of the KIPM. Ultimately, the novel analytical capabilities of this technology will allow for a better understanding of novel biomarkers, such EVs or lipid/polymer nanoparticles allowing for concentration and payload determinations.